Nuveen Asset Management LLC Sells 27,888 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Nuveen Asset Management LLC reduced its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 7.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 331,675 shares of the biotechnology company's stock after selling 27,888 shares during the quarter. Nuveen Asset Management LLC owned about 0.74% of United Therapeutics worth $117,028,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $25,000. Dunhill Financial LLC increased its holdings in shares of United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares in the last quarter. Millstone Evans Group LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $67,000. MassMutual Private Wealth & Trust FSB increased its holdings in shares of United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 58 shares in the last quarter. Finally, Natixis bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $85,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Up 1.4%

United Therapeutics stock traded up $4.26 during midday trading on Tuesday, reaching $309.57. The stock had a trading volume of 372,454 shares, compared to its average volume of 443,530. United Therapeutics Co. has a 12 month low of $264.33 and a 12 month high of $417.82. The firm's 50-day moving average price is $299.92 and its 200 day moving average price is $339.72. The firm has a market capitalization of $13.96 billion, a PE ratio of 13.60, a P/E/G ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. During the same period in the previous year, the business posted $6.17 EPS. The firm's quarterly revenue was up 17.2% compared to the same quarter last year. Equities research analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Activity at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. The trade was a 22.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 55,500 shares of company stock worth $17,054,780. 10.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a research report on Monday, April 21st. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. JPMorgan Chase & Co. cut their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Finally, HC Wainwright reiterated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research note on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $392.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.